GenIP PLC - New Product Launch – Invention Validator

GenIP Plc
("GenIP" or the "Company")
New Product Launch - Invention Validator
GenIP Plc, a technology consultancy providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce the launch of 'Invention Validator', a premium product designed to test user perception and adoption readiness of new technological discoveries. The inaugural project is with a research university in
The new service, which is currently being pilot tested, combines GenIP's established Invention Evaluator report with customised market and validation research and has an entry price point in excess of
It works in two steps:
1. a comprehensive evaluation of technical merit, IP strength, and market potential;
2. a structured collection and assessment of data from target end-users to validate adoption readiness.
GenIP designed a structured questionnaire, which is being distributed to farmers who are the end users and target customers for the new technology. The questionnaire will capture feedback on pricing, adoption barriers, and purchase intent. The responses will be analysed alongside the Invention Evaluator report on the technology. GenIP's Invention Validator will deliver strategic recommendations on commercialization approach, pricing strategy, and partnership priorities to the technology owner.
While the first application targets agriculture, it is anticipated that the methodology can be applied to various sectors, including medical devices, renewable energy systems, advanced materials, environmental monitoring tools, and digital health platforms. Whilst still in pilot launch stage, three universities in the
The service is designed as a high-margin, replicable offering, building on GenIP's proprietary technology ranking system already tested and proven from other consulting work. AI-powered automation reduces consulting overheads while maintaining the strategic depth expected by our clients.
Pricing varies by project scope, number of technologies assessed, and validation depth required, with all packages including the foundational Invention Evaluator report.
The launch of 'Invention Validator' is the next step in delivering a suite of new products under GenIP's AI-powered platform, as set out in our recently announced commercial strategy.
"This new product marks an important milestone in GenIP's evolution from delivering standalone reports to becoming an embedded partner in our clients' commercialization decisions.
Many technologies fail because research teams have to choose between slow, expensive market studies or risky assumptions about user adoption. Invention Validator bridges that gap by delivering fast, actionable insights by pairing AI driven analysis with real user feedback.
Invention Validator is strategically significant because it builds directly on our Invention Evaluator foundation. Organizations start with our core report, then progress naturally to Invention Validator to test real-world adoption. This progression from evaluation to validation and through to execution, creates the opportunity for recurring revenues to drive our growth strategy.
Universities have been asking for this capability and we have demonstrated this demand through its inaugural engagement. As we scale Invention Validator, we are building the high-value, repeatable client journeys that unlock sustained revenue growth."
For further information regarding GenIP, please visit www.genip.ai, or contact:
|
GenIP Plc |
|
Via Redchurch Communications |
|
|
|
|
|
Beaumont Cornish Limited (Nominated Adviser)
|
|
Tel: +44 (0) 20 7628 3396
|
|
AlbR Capital Limited (Broker) |
|
Tel: +44 (0)20 7399 9427
|
|
Redchurch Communications (Financial PR)
|
|
|
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
Notes to Editors
About GenIP
GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
|
Service |
Description |
Value Proposition |
|
Invention Intelligence Product Suite |
AI-powered market intelligence reports assessing the commercial potential of emerging technologies |
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
|
Talent and Executive Search Services |
Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership |
De-risks scaling by aligning technical vision with proven executive capability |
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
● Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
● Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
● Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
Forward looking statements
Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.
Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".
For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.
-ENDS-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE